Guerbet S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBT.PA research report →
About the company
Guerbet SA is dedicated to the development and commercialization of a broad spectrum of contrast media, advanced delivery systems, medical devices, and related solutions for diagnostic imaging. Their extensive product lineup features iodinated contrast agents such as Optiray and Xenetix, both non-ionic monomeric; Telebrix Gastro, a meglumine ioxitalamate solution; and Conray, an iothalamate meglumine injection. They also offer Micropaque/Microtrast, an integrated diagnostic imaging solution.
- CEO
- Philippe Bourrinet
- IPO
- 2000
- Employees
- 2,778
- HQ
- Villepinte, FR
Price Chart
- Market Cap
- $115.71M
- P/E
- -1.07
- P/S
- 0.15
- P/B
- 0.43
- EV/EBITDA
- 7.81
- Div Yield
- 0.00%
- Gross Margin
- 23.40%
- Op Margin
- 0.17%
- Net Margin
- -13.78%
- ROE
- -33.69%
- ROIC
- 0.18%
- Revenue
- $786.40M · -7.60%
- Net Income
- $-108,331,000 · -773.53%
- EPS
- $-8.59 · -771.09%
- Op Income
- $1.36M
- FCF YoY
- 9.60%
- 52W High
- $23.70
- 52W Low
- $8.01
- 50D MA
- $10.24
- 200D MA
- $12.79
- Beta
- 0.99
- Avg Volume
- 14.91K
Get TickerSpark's AI analysis on GBT.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GBT.PA coverage
Recent articles, reports, and earnings notes.
No research on GBT.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GBT.PA report →Similar companies
Peers in the same neighborhood.